Treats hypertension. ANDA 202725, held by Aurobindo Pharma Ltd. Quinapril Hydrochloride.
As of Nov 16, 2026, ANDA 202725 (Quinapril Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Apr 29, 2013, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2013 | Original application | Approved | None posted |
| Quinapril HydrochlorideEQ 5MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Quinapril HydrochlorideEQ 10MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Quinapril HydrochlorideEQ 20MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Quinapril HydrochlorideEQ 40MG BASE · tablet;oral | Quinapril Hydrochloride | Rx |
| Mar 31, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jun 8, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 8, 2018 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 24, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 24, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 26, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 26, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 29, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters